



Clinical trial results:

A Phase 2, Open-Label Study to Evaluate the Long-term Safety of Oral BCX9930 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Summary

| | |
|--------------------------|-----------------|
| EudraCT number | 2020-000501-93 |
| Trial protocol | GB AT DK IT |
| Global end of trial date | 04 October 2023 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v1 |
| This version publication date | 19 October 2024 |
| First version publication date | 19 October 2024 |

Trial information

Trial identification

| | |
|-----------------------|-------------|
| Sponsor protocol code | BCX9930-201 |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04702568 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | BioCryst Pharmaceuticals Inc. |
| Sponsor organisation address | 4505 Emperor Blvd., Suite 200, Durham, United States, NC 27703 |
| Public contact | BioCryst Pharmaceuticals Inc, Study Director, +001 919859 1302, clinicaltrials@biocryst.com |
| Scientific contact | BioCryst Pharmaceuticals Inc, Study Director, +001 919859 1302, clinicaltrials@biocryst.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 04 October 2023 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|-----------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 04 October 2023 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

To assess long-term safety and tolerability data in eligible participants with paroxysmal nocturnal hemoglobinuria (PNH) who previously received BCX9930 in a BioCryst-sponsored study and derived benefit from BCX9930 treatment.

Protection of trial subjects:

This trial was conducted in compliance with International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines for conducting, recording, and reporting trials, and in accordance with the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 18 December 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | United Kingdom: 5 |
| Country: Number of subjects enrolled | Austria: 2 |
| Country: Number of subjects enrolled | South Africa: 12 |
| Worldwide total number of subjects | 19 |
| EEA total number of subjects | 2 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 18 |
| From 65 to 84 years | 1 |

| | |
|-------------------|---|
| 85 years and over | 0 |
|-------------------|---|

Subject disposition

Recruitment

Recruitment details:

Participants who had participated in previous BCX9930 trials (BCX9930-101 [NCT04330534], BCX9930-202 [NCT05116774], or BCX9930-203 [NCT05116787]) for Paroxysmal Nocturnal Hemoglobinuria (PNH) and showed a benefit of treatment as determined by the investigator were enrolled in this long-term safety trial.

Pre-assignment

Screening details:

A total of 19 participants were treated.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|--|
| Are arms mutually exclusive? | Yes |
| Arm title | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group |

Arm description:

This group included participants who, prior to enrolling in their previous BCX9930 study, were either naïve to eculizumab or ravulizumab treatment, or naïve to treatment with any complement inhibitor therapy (or had received no treatment in the prior 12 months), and with anemia due to ongoing intravascular hemolysis. Participants were to commence treatment at the same BCX9930 dose level and regimen last administered to that individual in the prior study. Per last protocol amendment, all participants received BCX9930 400 milligrams (mg) orally twice daily (BID). Treatment duration was up to 144 weeks.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | BCX9930 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Administered orally twice daily.

| | |
|------------------|----------------------------------|
| Arm title | C5 INH Inadequate Response Group |
|------------------|----------------------------------|

Arm description:

This group included participants who, prior to enrolling in their previous BCX9930 study, were receiving stable treatment with eculizumab or ravulizumab and had an inadequate response to that therapy (ie, residual anemia and/or ongoing need for transfusion). Depending on the prior study, participants may have continued the C5 inhibitor, with BCX9930 provided as an add-on therapy. Participants were to commence treatment at the same BCX9930 dose level and regimen last administered to that individual in the prior study. Per last protocol amendment, all participants received BCX9930 400 mg orally BID. Treatment duration was up to 144 weeks.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | BCX9930 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Other use |

Dosage and administration details:

Administered orally twice daily.

| Number of subjects in period 1 | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group |
|---|--|----------------------------------|
| | | |
| Started | 12 | 7 |
| Completed | 0 | 0 |
| Not completed | 12 | 7 |
| Pregnancy | 1 | - |
| Transitioned to the BCX9930-205 roll-over study | 10 | 4 |
| Withdrawal by Subject | - | 2 |
| Withdrawn due to Investigator decision | - | 1 |
| Bone marrow transplant | 1 | - |

Baseline characteristics

Reporting groups

| | |
|-----------------------|--|
| Reporting group title | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group |
|-----------------------|--|

Reporting group description:

This group included participants who, prior to enrolling in their previous BCX9930 study, were either naïve to eculizumab or ravulizumab treatment, or naïve to treatment with any complement inhibitor therapy (or had received no treatment in the prior 12 months), and with anemia due to ongoing intravascular hemolysis. Participants were to commence treatment at the same BCX9930 dose level and regimen last administered to that individual in the prior study. Per last protocol amendment, all participants received BCX9930 400 milligrams (mg) orally twice daily (BID). Treatment duration was up to 144 weeks.

| | |
|-----------------------|----------------------------------|
| Reporting group title | C5 INH Inadequate Response Group |
|-----------------------|----------------------------------|

Reporting group description:

This group included participants who, prior to enrolling in their previous BCX9930 study, were receiving stable treatment with eculizumab or ravulizumab and had an inadequate response to that therapy (ie, residual anemia and/or ongoing need for transfusion). Depending on the prior study, participants may have continued the C5 inhibitor, with BCX9930 provided as an add-on therapy. Participants were to commence treatment at the same BCX9930 dose level and regimen last administered to that individual in the prior study. Per last protocol amendment, all participants received BCX9930 400 mg orally BID. Treatment duration was up to 144 weeks.

| Reporting group values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | Total |
|--|--|----------------------------------|-------|
| Number of subjects | 12 | 7 | 19 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 12 | 6 | 18 |
| From 65-84 years | 0 | 1 | 1 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous Units: years | | | |
| arithmetic mean | 29.3 | 44.6 | |
| standard deviation | ± 7.82 | ± 18.59 | - |
| Gender categorical Units: Subjects | | | |
| Female | 3 | 5 | 8 |
| Male | 9 | 2 | 11 |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 12 | 7 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 2 | 9 |
| White | 3 | 4 | 7 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |

End points

End points reporting groups

| | |
|-----------------------|--|
| Reporting group title | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group |
|-----------------------|--|

Reporting group description:

This group included participants who, prior to enrolling in their previous BCX9930 study, were either naïve to eculizumab or ravulizumab treatment, or naïve to treatment with any complement inhibitor therapy (or had received no treatment in the prior 12 months), and with anemia due to ongoing intravascular hemolysis. Participants were to commence treatment at the same BCX9930 dose level and regimen last administered to that individual in the prior study. Per last protocol amendment, all participants received BCX9930 400 milligrams (mg) orally twice daily (BID). Treatment duration was up to 144 weeks.

| | |
|-----------------------|----------------------------------|
| Reporting group title | C5 INH Inadequate Response Group |
|-----------------------|----------------------------------|

Reporting group description:

This group included participants who, prior to enrolling in their previous BCX9930 study, were receiving stable treatment with eculizumab or ravulizumab and had an inadequate response to that therapy (ie, residual anemia and/or ongoing need for transfusion). Depending on the prior study, participants may have continued the C5 inhibitor, with BCX9930 provided as an add-on therapy. Participants were to commence treatment at the same BCX9930 dose level and regimen last administered to that individual in the prior study. Per last protocol amendment, all participants received BCX9930 400 mg orally BID. Treatment duration was up to 144 weeks.

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

| | |
|-----------------|--|
| End point title | Number of Participants With Treatment Emergent Adverse Events (TEAEs) ^[1] |
|-----------------|--|

End point description:

An AE was defined as any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related in a participant or clinical investigation participant who administered a pharmaceutical product regardless of its causal relationship to the study treatment. An AE was considered treatment emergent if its start date and time was on or after the date and time of first on-study dose of study drug. The safety population included all participants who received at least 1 capsule or tablet of study drug.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From first dose of study drug up to 3 weeks after last dose (Week 147)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There was no formal hypothesis testing and only descriptive analyses was performed.

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|-----------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: participants | | | | |
| number (not applicable) | 12 | 7 | | |

Statistical analyses

Secondary: Number of Participants with Clinical PNH Symptom Based on Severity: Fatigue

| | |
|-----------------|---|
| End point title | Number of Participants with Clinical PNH Symptom Based on Severity: Fatigue |
|-----------------|---|

End point description:

Data was reported for number of participants with clinical PNH symptom of fatigue. The severity of clinical PNH symptom of fatigue was graded as none, mild, moderate and severe based solely on investigator's discretion. mITT population included all participants who received at least 1 capsule or tablet of study drug and had post baseline assessment of PNH symptoms and/or laboratory data. Participants with available data at each visit were included.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 24, 48, 72, 96, and 120

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|-----------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: participants | | | | |
| number (not applicable) | | | | |
| Baseline-none (n=12,7) | 8 | 6 | | |
| Baseline-mild (n=12,7) | 3 | 2 | | |
| Baseline-moderate (n=12,7) | 0 | 1 | | |
| Baseline-severe (n=12,7) | 1 | 0 | | |
| Week 24-none (n=12,7) | 10 | 3 | | |
| Week 24-mild (n=12,7) | 2 | 3 | | |
| Week 24-moderate (n=12,7) | 0 | 1 | | |
| Week 24-severe (n=12,7) | 0 | 0 | | |
| Week 48-none (n=8,3) | 6 | 2 | | |
| Week 48-mild (n=8,3) | 2 | 0 | | |
| Week 48-moderate (n=8,3) | 0 | 1 | | |
| Week 48-severe (n=8,3) | 0 | 0 | | |
| Week 72-none (n=8,3) | 7 | 1 | | |
| Week 72-mild (n=8,3) | 1 | 2 | | |
| Week 72-moderate (n=8,3) | 0 | 0 | | |
| Week 72-severe (n=8,3) | 0 | 0 | | |
| Week 96-none (n=8,3) | 6 | 2 | | |
| Week 96-mild (n=8,3) | 2 | 0 | | |
| Week 96-moderate (n=8,3) | 0 | 0 | | |
| Week 96-severe (n=8,3) | 0 | 1 | | |
| Week 120-none (n=8,3) | 8 | 2 | | |
| Week 120-mild (n=8,3) | 0 | 0 | | |
| Week 120-moderate (n=8,3) | 0 | 1 | | |
| Week 120-severe (n=8,3) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Clinical PNH Symptom Based on Severity: Dyspnea

| | |
|-----------------|---|
| End point title | Number of Participants with Clinical PNH Symptom Based on Severity: Dyspnea |
|-----------------|---|

End point description:

Data was reported for number of participants with clinical PNH symptom of dyspnea. The severity of clinical PNH symptom of dyspnea was graded as none, mild, moderate and severe based solely on investigator's discretion. Participants in the mITT population with available data were analyzed.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 24, 48, 72, 96, and 120

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|-----------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: participants | | | | |
| number (not applicable) | | | | |
| Baseline-none (n=12,7) | 11 | 7 | | |
| Baseline-mild (n=12,7) | 1 | 0 | | |
| Baseline-moderate (n=12,7) | 0 | 0 | | |
| Baseline-severe (n=12,7) | 0 | 0 | | |
| Week 24-none (n=12,7) | 11 | 7 | | |
| Week 24-mild (n=12,7) | 1 | 0 | | |
| Week 24-moderate (n=12,7) | 0 | 0 | | |
| Week 24-severe (n=12,7) | 0 | 0 | | |
| Week 48-none (n=8,3) | 6 | 2 | | |
| Week 48-mild (n=8,3) | 2 | 1 | | |
| Week 48-moderate (n=8,3) | 0 | 0 | | |
| Week 48-severe (n=8,3) | 0 | 0 | | |
| Week 72-none (n=8,3) | 7 | 2 | | |
| Week 72-mild (n=8,3) | 1 | 1 | | |
| Week 72-moderate (n=8,3) | 0 | 0 | | |
| Week 72-severe (n=8,3) | 0 | 0 | | |
| Week 96-none (n=8,3) | 7 | 2 | | |
| Week 96-mild (n=8,3) | 0 | 0 | | |
| Week 96-moderate (n=8,3) | 1 | 1 | | |

| | | | | |
|---------------------------|---|---|--|--|
| Week 96-severe (n=8,3) | 0 | 0 | | |
| Week 120-none (n=8,3) | 8 | 2 | | |
| Week 120-mild (n=8,3) | 0 | 1 | | |
| Week 120-moderate (n=8,3) | 0 | 0 | | |
| Week 120-severe (n=8,3) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Clinical PNH Symptom Based on Severity: Chest Pain/Discomfort

| | |
|-----------------|---|
| End point title | Number of Participants with Clinical PNH Symptom Based on Severity: Chest Pain/Discomfort |
|-----------------|---|

End point description:

Data was reported for number of participants with clinical PNH symptom of chest pain/discomfort. The severity of clinical PNH symptom of chest pain/discomfort was graded as none, mild, moderate and severe based solely on investigator's discretion. Participants in the mITT population with available data were analyzed.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 24, 48, 72, 96, and 12

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|-----------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: participants | | | | |
| number (not applicable) | | | | |
| Baseline-none (n=12,7) | 12 | 7 | | |
| Baseline-mild (n=12,7) | 0 | 0 | | |
| Baseline-moderate (n=12,7) | 0 | 0 | | |
| Baseline-severe (n=12,7) | 0 | 0 | | |
| Week 24-none (n=12,7) | 12 | 7 | | |
| Week 24-mild (n=12,7) | 0 | 0 | | |
| Week 24-moderate (n=12,7) | 0 | 0 | | |
| Week 24-severe (n=12,7) | 0 | 0 | | |
| Week 48-none (n=8,3) | 7 | 2 | | |
| Week 48-mild (n=8,3) | 1 | 1 | | |
| Week 48-moderate (n=8,3) | 0 | 0 | | |
| Week 48-severe (n=8,3) | 0 | 0 | | |
| Week 72-none (n=8,3) | 7 | 2 | | |
| Week 72-mild (n=8,3) | 1 | 0 | | |
| Week 72-moderate (n=8,3) | 0 | 1 | | |
| Week 72-severe (n=8,3) | 0 | 0 | | |
| Week 96-none (n=8,3) | 7 | 3 | | |

| | | | | |
|---------------------------|---|---|--|--|
| Week 96-mild (n=8,3) | 1 | 0 | | |
| Week 96-moderate (n=8,3) | 0 | 0 | | |
| Week 96-severe (n=8,3) | 0 | 0 | | |
| Week 120-none (n=8,3) | 8 | 3 | | |
| Week 120-mild (n=8,3) | 0 | 0 | | |
| Week 120-moderate (n=8,3) | 0 | 0 | | |
| Week 120-severe (n=8,3) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Clinical PNH Symptom Based on Severity: Difficulty Swallowing

| | |
|-----------------|---|
| End point title | Number of Participants with Clinical PNH Symptom Based on Severity: Difficulty Swallowing |
|-----------------|---|

End point description:

Data was reported for number of participants with clinical PNH symptom of difficulty swallowing. The severity of clinical PNH symptom of difficulty swallowing was graded as none, mild, moderate and severe based solely on investigator's discretion. Participants in the mITT population with available data were analyzed.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 24, 48, 72, 96, and 120

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|-----------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: participants | | | | |
| number (not applicable) | | | | |
| Baseline-none (n=12,7) | 11 | 6 | | |
| Baseline-mild (n=12,7) | 1 | 1 | | |
| Baseline-moderate (n=12,7) | 0 | 0 | | |
| Baseline-severe (n=12,7) | 0 | 0 | | |
| Week 24-none (n=12,7) | 12 | 7 | | |
| Week 24-mild (n=12,7) | 0 | 0 | | |
| Week 24-moderate (n=12,7) | 0 | 0 | | |
| Week 24-severe (n=12,7) | 0 | 0 | | |
| Week 48-none (n=8,3) | 6 | 2 | | |
| Week 48-mild (n=8,3) | 2 | 1 | | |
| Week 48-moderate (n=8,3) | 0 | 0 | | |
| Week 48-severe (n=8,3) | 0 | 0 | | |
| Week 72-none (n=8,3) | 7 | 2 | | |
| Week 72-mild (n=8,3) | 1 | 1 | | |
| Week 72-moderate (n=8,3) | 0 | 0 | | |

| | | | | |
|---------------------------|---|---|--|--|
| Week 72-severe (n=8,3) | 0 | 0 | | |
| Week 96-none (n=8,3) | 7 | 2 | | |
| Week 96-mild (n=8,3) | 1 | 1 | | |
| Week 96-moderate (n=8,3) | 0 | 0 | | |
| Week 96-severe (n=8,3) | 0 | 0 | | |
| Week 120-none (n=8,3) | 8 | 3 | | |
| Week 120-mild (n=8,3) | 0 | 0 | | |
| Week 120-moderate (n=8,3) | 0 | 0 | | |
| Week 120-severe (n=8,3) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Clinical PNH Symptom Based on Severity: Abdominal Pain

| | |
|-----------------|--|
| End point title | Number of Participants with Clinical PNH Symptom Based on Severity: Abdominal Pain |
|-----------------|--|

End point description:

Data was reported for number of participants with clinical PNH symptom of abdominal pain. The severity of clinical PNH symptom of abdominal pain was graded as none, mild, moderate and severe based solely on investigator's discretion. Participants in the mITT population with available data were analyzed.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 24, 48, 72, 96, and 120

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|-----------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: participants | | | | |
| number (not applicable) | | | | |
| Baseline-none (n=12,7) | 10 | 7 | | |
| Baseline-mild (n=12,7) | 1 | 0 | | |
| Baseline-moderate (n=12,7) | 1 | 0 | | |
| Baseline-severe (n=12,7) | 0 | 0 | | |
| Week 24-none (n=12,7) | 9 | 6 | | |
| Week 24-mild (n=12,7) | 2 | 0 | | |
| Week 24-moderate (n=12,7) | 1 | 1 | | |
| Week 24-severe (n=12,7) | 0 | 0 | | |
| Week 48-none (n=8,3) | 6 | 2 | | |
| Week 48-mild (n=8,3) | 1 | 1 | | |
| Week 48-moderate (n=8,3) | 0 | 0 | | |
| Week 48-severe (n=8,3) | 1 | 0 | | |
| Week 72-none (n=8,3) | 7 | 2 | | |
| Week 72-mild (n=8,3) | 1 | 1 | | |

| | | | | |
|---------------------------|---|---|--|--|
| Week 72-moderate (n=8,3) | 0 | 0 | | |
| Week 72-severe (n=8,3) | 0 | 0 | | |
| Week 96-none (n=8,3) | 7 | 2 | | |
| Week 96-mild (n=8,3) | 1 | 1 | | |
| Week 96-moderate (n=8,3) | 0 | 0 | | |
| Week 96-severe (n=8,3) | 0 | 0 | | |
| Week 120-none (n=8,3) | 8 | 3 | | |
| Week 120-mild (n=8,3) | 0 | 0 | | |
| Week 120-moderate (n=8,3) | 0 | 0 | | |
| Week 120-severe (n=8,3) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Clinical PNH Symptom Based on Severity: Headache

| | |
|-----------------|--|
| End point title | Number of Participants With Clinical PNH Symptom Based on Severity: Headache |
|-----------------|--|

End point description:

Data was reported for number of participants with clinical PNH symptom of headache. The severity of clinical PNH symptom of headache was graded as none, mild, moderate and severe based solely on investigator's discretion. Participants in the mITT population with available data were analyzed.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 24, 48, 72, 96, and 120

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|-----------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: participants | | | | |
| number (not applicable) | | | | |
| Baseline-none (n=12,7) | 10 | 7 | | |
| Baseline-mild (n=12,7) | 2 | 0 | | |
| Baseline-moderate (n=12,7) | 0 | 0 | | |
| Baseline-severe (n=12,7) | 0 | 0 | | |
| Week 24-none (n=12,7) | 11 | 6 | | |
| Week 24-mild (n=12,7) | 1 | 1 | | |
| Week 24-moderate (n=12,7) | 0 | 0 | | |
| Week 24-severe (n=12,7) | 0 | 0 | | |
| Week 48-none (n=8,3) | 7 | 2 | | |
| Week 48-mild (n=8,3) | 0 | 0 | | |
| Week 48-moderate (n=8,3) | 1 | 1 | | |
| Week 48-severe (n=8,3) | 0 | 0 | | |
| Week 72-none (n=8,3) | 8 | 3 | | |

| | | | | |
|---------------------------|---|---|--|--|
| Week 72-mild (n=8,3) | 0 | 0 | | |
| Week 72-moderate (n=8,3) | 0 | 0 | | |
| Week 72-severe (n=8,3) | 0 | 0 | | |
| Week 96-none (n=8,3) | 7 | 3 | | |
| Week 96-mild (n=8,3) | 1 | 0 | | |
| Week 96-moderate (n=8,3) | 0 | 0 | | |
| Week 96-severe (n=8,3) | 0 | 0 | | |
| Week 120-none (n=8,3) | 8 | 2 | | |
| Week 120-mild (n=8,3) | 0 | 1 | | |
| Week 120-moderate (n=8,3) | 0 | 0 | | |
| Week 120-severe (n=8,3) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Clinical PNH Symptom Based on Severity: Erectile Dysfunction

| | |
|-----------------|--|
| End point title | Number of Participants with Clinical PNH Symptom Based on Severity: Erectile Dysfunction |
|-----------------|--|

End point description:

Data was reported for number of participants with clinical PNH symptom of erectile dysfunction. The severity of clinical PNH symptom of erectile dysfunction was graded as none, mild, moderate and severe based solely on investigator's discretion. Participants in the mITT population with available data were analyzed.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 24, 48, 72, 96, and 120

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|-----------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: participants | | | | |
| number (not applicable) | | | | |
| Baseline-none (n=9,2) | 9 | 2 | | |
| Baseline-mild (n=9,2) | 0 | 0 | | |
| Baseline-moderate (n=9,2) | 0 | 0 | | |
| Baseline-severe (n=9,2) | 0 | 0 | | |
| Week 24-none (n=9,2) | 9 | 2 | | |
| Week 24-mild (n=9,2) | 0 | 0 | | |
| Week 24-moderate (n=9,2) | 0 | 0 | | |
| Week 24-severe (n=9,2) | 0 | 0 | | |
| Week 48-none (n=8,1) | 7 | 1 | | |
| Week 48-mild (n=8,1) | 1 | 0 | | |
| Week 48-moderate (n=8,1) | 0 | 0 | | |

| | | | | |
|---------------------------|---|---|--|--|
| Week 48- severe (n=8,1) | 0 | 0 | | |
| Week 72-none (n=8,1) | 7 | 1 | | |
| Week 72-mild (n=8,1) | 1 | 0 | | |
| Week 72-moderate (n=8,1) | 0 | 0 | | |
| Week 72-severe (n=8,1) | 0 | 0 | | |
| Week 96-none (n=8,2) | 7 | 2 | | |
| Week 96-mild (n=8,2) | 1 | 0 | | |
| Week 96-moderate (n=8,2) | 0 | 0 | | |
| Week 96-severe (n=8,2) | 0 | 0 | | |
| Week 120-none (n=8,1) | 7 | 1 | | |
| Week 120-mild (n=8,1) | 1 | 0 | | |
| Week 120-moderate (n=8,1) | 0 | 0 | | |
| Week 120-severe (n=8,1) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Clinical PNH Symptom Based on Severity: Hemoglobinuria

| | |
|-----------------|--|
| End point title | Number of Participants with Clinical PNH Symptom Based on Severity: Hemoglobinuria |
|-----------------|--|

End point description:

Data was reported for number of participants with clinical PNH symptom of hemoglobinuria. The severity of clinical PNH symptom of hemoglobinuria was graded as none, mild, moderate and severe based solely on investigator's discretion. Participants in the mITT population with available data were analyzed.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 24, 48, 72, 96, and 120

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|------------------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: participants | | | | |
| number (not applicable) | | | | |
| Baseline-none (n=12,7) | 10 | 7 | | |
| Baseline-mild (n=12,7) | 0 | 0 | | |
| Baseline-moderate (n=12,7) | 0 | 0 | | |
| Baseline-severe (n=12,7) | 0 | 0 | | |
| Baseline-missing severity (n=12,6) | 2 | 0 | | |
| Week 24-none (n=12,7) | 11 | 5 | | |
| Week 24-mild (n=12,7) | 0 | 0 | | |
| Week 24-moderate (n=12,7) | 0 | 0 | | |
| Week 24-severe (n=12,7) | 0 | 0 | | |
| Week 24-missing severity (n=12,7) | 1 | 2 | | |

| | | | | |
|-----------------------------------|---|---|--|--|
| Week 48-none (n=8,3) | 6 | 3 | | |
| Week 48-mild (n=8,3) | 0 | 0 | | |
| Week 48-moderate (n=8,3) | 1 | 0 | | |
| Week 48- severe (n=8,3) | 0 | 0 | | |
| Week 48-missing severity (n=8,3) | 1 | 0 | | |
| Week 72-none (n=8,3) | 7 | 2 | | |
| Week 72-mild (n=8,3) | 0 | 1 | | |
| Week 72-moderate (n=8,3) | 0 | 0 | | |
| Week 72-severe (n=8,3) | 0 | 0 | | |
| Week 72-missing severity (n=8,3) | 1 | 0 | | |
| Week 96-none (n=8,3) | 6 | 3 | | |
| Week 96-mild (n=8,3) | 0 | 0 | | |
| Week 96-moderate (n=8,3) | 0 | 0 | | |
| Week 96-severe (n=8,3) | 0 | 0 | | |
| Week 96-missing severity (n=8,3) | 2 | 0 | | |
| Week 120-none (n=8,3) | 7 | 3 | | |
| Week 120-mild (n=8,3) | 0 | 0 | | |
| Week 120-moderate (n=8,3) | 0 | 0 | | |
| Week 120-severe (n=8,3) | 0 | 0 | | |
| Week 120-missing severity (n=8,3) | 1 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Clinical PNH Symptom Based on Severity: Jaundice

| | |
|-----------------|--|
| End point title | Number of Participants with Clinical PNH Symptom Based on Severity: Jaundice |
|-----------------|--|

End point description:

Data was reported for number of participants with clinical PNH symptom of jaundice. The severity of clinical PNH symptom of jaundice was graded as none, mild, moderate and severe based solely on investigator's discretion. Participants in the population with available data were analyzed.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 24, 48, 72, 96, and 120

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|-----------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: participants | | | | |
| number (not applicable) | | | | |
| Baseline-none (n=12,7) | 11 | 7 | | |
| Baseline-mild (n=12,7) | 0 | 0 | | |
| Baseline-moderate (n=12,7) | 0 | 0 | | |

| | | | | |
|------------------------------------|----|---|--|--|
| Baseline-severe (n=12,7) | 0 | 0 | | |
| Baseline-missing severity (n=12,7) | 1 | 0 | | |
| Week 24-none (n=12,7) | 12 | 7 | | |
| Week 24-mild (n=12,7) | 0 | 0 | | |
| Week 24-moderate (n=12,7) | 0 | 0 | | |
| Week 24-severe (n=12,7) | 0 | 0 | | |
| Week 48-none (n=8,3) | 8 | 3 | | |
| Week 48-mild (n=8,3) | 0 | 0 | | |
| Week 48-moderate (n=8,3) | 0 | 0 | | |
| Week 48- severe (n=8,3) | 0 | 0 | | |
| Week 72-none (n=8,3) | 8 | 3 | | |
| Week 72-mild (n=8,3) | 0 | 0 | | |
| Week 72-moderate (n=8,3) | 0 | 0 | | |
| Week 72-severe (n=8,3) | 0 | 0 | | |
| Week 96-none (n=8,3) | 8 | 3 | | |
| Week 96-mild (n=8,3) | 0 | 0 | | |
| Week 96-moderate (n=8,3) | 0 | 0 | | |
| Week 96-severe (n=8,3) | 0 | 0 | | |
| Week 120-none (n=8,3) | 8 | 3 | | |
| Week 120-mild (n=8,3) | 0 | 0 | | |
| Week 120-moderate (n=8,3) | 0 | 0 | | |
| Week 120-severe (n=8,3) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Lactate Dehydrogenase (LDH)

| | |
|-----------------|---|
| End point title | Change From Baseline in Lactate Dehydrogenase (LDH) |
|-----------------|---|

End point description:

Participants in the mITT population with available data were analyzed. Here "99999" represents that mean and standard deviation (SD) was not estimable as there were less than 2 participants at the given timepoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks, 24, 48, 72, 96, 120, and 144

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|--------------------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 6 | | |
| Units: Units per liter (U/L) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=12,6) | 475.6 (± 210.98) | 248.3 (± 125.71) | | |

| | | | | |
|----------------------------|------------------|------------------|--|--|
| Change at Week 24 (n=11,5) | -46.7 (± 154.55) | 38.6 (± 45.51) | | |
| Change at Week 48 (n=8,2) | -62.5 (± 80.97) | 38.5 (± 65.76) | | |
| Change at Week 72 (n=8,2) | -6.1 (± 238.41) | 163.5 (± 118.09) | | |
| Change at Week 96 (n=8,2) | 237.4 (± 347.65) | -4.0 (± 134.35) | | |
| Change at Week 120 (n=8,2) | 195.4 (± 355.03) | 31.0 (± 125.87) | | |
| Change at Week 144 (n=1,0) | -59.0 (± 99999) | 99999 (± 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Hemoglobin

| | |
|--|------------------------------------|
| End point title | Change From Baseline in Hemoglobin |
| End point description: | |
| Participants in the mITT population with available data were analyzed. Here "99999" represents that mean and SD was not estimable as there were less than 2 participants at the given timepoint. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Weeks 24, 48, 72, 96, 120, and 144 | |

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|--------------------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: grams per deciliter (g/dl) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=12,7) | 11.88 (± 1.688) | 11.53 (± 1.803) | | |
| Change at Week 24 (n=11,6) | 0.75 (± 1.159) | -1.32 (± 2.578) | | |
| Change at Week 48 (n=8,2) | -0.61 (± 1.974) | -0.95 (± 2.333) | | |
| Change at Week 72 (n=8,3) | -0.64 (± 2.327) | -0.93 (± 1.484) | | |
| Change at Week 96 (n=8,2) | -0.33 (± 1.914) | -0.70 (± 2.687) | | |
| Change at Week 120 (n=8,3) | 0.38 (± 1.555) | -0.47 (± 2.098) | | |
| Change at Week 144 (n=1,0) | -2.70 (± 99999) | 99999 (± 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Haptoglobin

| | |
|-----------------|-------------------------------------|
| End point title | Change From Baseline in Haptoglobin |
|-----------------|-------------------------------------|

End point description:

Participants in the mITT population with available data were analyzed. Here "99999" represents that mean and SD was not estimable as there were less than 2 participants at the given timepoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 24, 48, 72, 96, and 120

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|--------------------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 5 | | |
| Units: grams per liter (g/L) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=12,5) | 0.325 (± 0.2832) | 0.216 (± 0.1350) | | |
| Change at Week 24 (n=11,5) | 0.000 (± 0.0447) | -0.082 (± 0.0844) | | |
| Change at Week 48 (n=8,0) | 0.213 (± 0.1126) | 99999 (± 99999) | | |
| Change at Week 72 (n=8,2) | 0.025 (± 0.1165) | -0.210 (± 0.1414) | | |
| Change at Week 96 (n=8,2) | -0.013 (± 0.0354) | 0.195 (± 0.4313) | | |
| Change at Week 120 (n=8,1) | -0.013 (± 0.0354) | -0.100 (± 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Reticulocytes

| | |
|-----------------|---------------------------------------|
| End point title | Change From Baseline in Reticulocytes |
|-----------------|---------------------------------------|

End point description:

Participants in the mITT population with available data were analyzed

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Weeks 24, 48, 72, 96, and 120 | |

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|--|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: 10 ⁶ cells per microliter (µL) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=12,7) | 0.1066 (± 0.02363) | 0.0889 (± 0.03939) | | |
| Change at Week 24 (n=11,6) | 0.0164 (± 0.02339) | 0.0913 (± 0.09144) | | |
| Change at Week 48 (n=8,2) | 0.0048 (± 0.03518) | 0.0507 (± 0.03161) | | |
| Change at Week 72 (n=8,3) | 0.0044 (± 0.03643) | 0.0463 (± 0.03008) | | |
| Change at Week 96 (n=8,2) | 0.0409 (± 0.03805) | 0.0607 (± 0.03585) | | |
| Change at Week 120 (n=8,3) | 0.0173 (± 0.03303) | 0.0653 (± 0.02380) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Blood Transfusions or Thromboses

| | |
|---|--|
| End point title | Number of Participants With Blood Transfusions or Thromboses |
| End point description: | |
| Data was reported for number of participants for whom blood transfusion was required or who experienced the thrombosis events. Participants in the mITT population with available data were analyzed. | |
| End point type | Secondary |
| End point timeframe: | |
| From first dose of study drug up to 3 weeks after last dose (Week 147) | |

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|-----------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 12 | 7 | | |
| Units: participants | | | | |

| | | | | |
|-------------------------|---|---|--|--|
| number (not applicable) | | | | |
| Blood transfusions | 3 | 4 | | |
| Thromboses | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Blood Transfusions

| | |
|---|------------------------------|
| End point title | Number of Blood Transfusions |
| End point description: Number of blood transfusions were reported. Participants from mITT population who required blood transfusions were evaluated. | |
| End point type | Secondary |
| End point timeframe: From first dose of study drug up to 3 weeks after last dose (Week 147) | |

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|-------------------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 4 | | |
| Units: Number of blood transfusions | | | | |
| number (not applicable) | | | | |
| Number of Blood Transfusion | 13 | 25 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Total Score

| | |
|---|--|
| End point title | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Total Score |
| End point description: The FACIT-Fatigue scale questionnaire was used to determine the level of fatigue experienced by participants. This questionnaire was a 13-item measure that assessed self-reported fatigue and its impact upon daily activities and function. Item scores ranged from 0 ("not at all") to 4 ("very much"), and the total score ranged from 0 to 52, with higher scores indicating greater quality of life. Participants in the mITT population with available data were analyzed. | |
| End point type | Secondary |
| End point timeframe: Baseline, Weeks 24, 48, 72, and 96 | |

| End point values | Complement Component 5 (C5) Inhibitor (C5-INH) Naïve Group | C5 INH Inadequate Response Group | | |
|--------------------------------------|--|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 11 | 7 | | |
| Units: Scores on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=11,7) | 43.82 (± 9.400) | 40.14 (± 13.533) | | |
| Change at Week 24 (n=11,7) | 0.09 (± 4.110) | -3.36 (± 8.066) | | |
| Change at Week 48 (n=8,3) | -0.63 (± 2.387) | 2.33 (± 3.215) | | |
| Change at Week 72 (n=8,3) | -0.38 (± 2.875) | -4.64 (± 12.016) | | |
| Change at Week 96 (n=8,3) | -1.13 (± 4.357) | -18.00 (± 27.185) | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug up to 3 weeks after last dose (Week 147)

Adverse event reporting additional description:

The safety analysis population included all participants who received at least 1 capsule or tablet of study drug.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|----|
| Dictionary version | 24 |
|--------------------|----|

Reporting groups

| | |
|-----------------------|--------------------|
| Reporting group title | C5-INH Naïve Group |
|-----------------------|--------------------|

Reporting group description:

This group included participants who, prior to enrolling in their previous BCX9930 study, were either naïve to eculizumab or ravulizumab treatment, or naïve to treatment with any complement inhibitor therapy (or had received no treatment in the prior 12 months), and with anemia due to ongoing intravascular hemolysis. Participants were to commence treatment at the same BCX9930 dose level and regimen last administered to that individual in the prior study. Per last protocol amendment, all participants received BCX9930 400 mg orally BID. Treatment duration was up to 144 weeks.

| | |
|-----------------------|----------------------------------|
| Reporting group title | C5-INH Inadequate Response Group |
|-----------------------|----------------------------------|

Reporting group description:

This group included participants who, prior to enrolling in their previous BCX9930 study, were receiving stable treatment with eculizumab or ravulizumab and had an inadequate response to that therapy (ie, residual anemia and/or ongoing need for transfusion). Depending on the prior study, participants may have continued the C5 inhibitor, with BCX9930 provided as an add-on therapy. Participants were to commence treatment at the same BCX9930 dose level and regimen last administered to that individual in the prior study. Per last protocol amendment, all participants were to receive BCX9930 400 mg orally BID. Treatment duration was up to 144 weeks.

| Serious adverse events | C5-INH Naïve Group | C5-INH Inadequate Response Group | |
|---|--------------------|----------------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 6 / 12 (50.00%) | 3 / 7 (42.86%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Epstein-Barr virus associated lymphoma | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Breakthrough haemolysis | | | |

| | | | |
|--|-----------------|----------------|--|
| subjects affected / exposed | 3 / 12 (25.00%) | 0 / 7 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemolysis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 7 (14.29%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Crohn's disease | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastritis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Boutonneuse fever | | | |

| | | | |
|---|----------------|----------------|--|
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sepsis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Soft tissue infection | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | C5-INH Naïve Group | C5-INH Inadequate Response Group | |
|---|--------------------|----------------------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 12 / 12 (100.00%) | 7 / 7 (100.00%) | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 7 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Vasculitis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| General disorders and administration site conditions | | | |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Chest discomfort | | | |

| | | | |
|--|----------------|----------------|--|
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Chest pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 7 (28.57%) | |
| occurrences (all) | 0 | 2 | |
| Condition aggravated | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 2 | |
| Fatigue | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 3 / 7 (42.86%) | |
| occurrences (all) | 0 | 8 | |
| Feeling abnormal | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 3 | |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 2 / 7 (28.57%) | |
| occurrences (all) | 1 | 3 | |
| Oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 2 | |
| Pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 3 | |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 2 / 7 (28.57%) | |
| occurrences (all) | 1 | 2 | |
| Immune system disorders | | | |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Reproductive system and breast disorders | | | |
| Erectile dysfunction | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Heavy menstrual bleeding | | | |

| | | | |
|---|-----------------|----------------|--|
| subjects affected / exposed | 1 / 12 (8.33%) | 2 / 7 (28.57%) | |
| occurrences (all) | 1 | 2 | |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 3 / 7 (42.86%) | |
| occurrences (all) | 1 | 8 | |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 3 / 7 (42.86%) | |
| occurrences (all) | 0 | 4 | |
| Painful respiration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 2 | |
| Productive cough | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Sinus disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Sinus pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 7 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Depression | | | |

| | | | |
|--|----------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 2 / 12 (16.67%) 3 | 1 / 7 (14.29%) 1 | |
| Insomnia subjects affected / exposed occurrences (all) | 2 / 12 (16.67%) 2 | 0 / 7 (0.00%) 0 | |
| Stress subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| Aspartate aminotransferase increased subjects affected / exposed occurrences (all) | 4 / 12 (33.33%) 4 | 0 / 7 (0.00%) 0 | |
| Blood alkaline phosphatase increased subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| Blood bilirubin increased subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| Blood creatinine increased subjects affected / exposed occurrences (all) | 5 / 12 (41.67%) 7 | 0 / 7 (0.00%) 0 | |
| Blood iron decreased subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| Blood uric acid increased subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| C-reactive protein increased subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| Creatinine urine increased | | | |

| | | | |
|--|-----------------|----------------|--|
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Fibrin D dimer increased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Glomerular filtration rate decreased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Haemoglobin decreased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Neutrophil count increased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| SARS-CoV-2 test positive | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Urine albumin/creatinine ratio increased | | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 0 / 7 (0.00%) | |
| occurrences (all) | 6 | 0 | |
| Weight increased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Injury, poisoning and procedural complications | | | |
| Arthropod bite | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Contusion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Joint injury | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Ligament sprain | | | |

| | | | |
|--|-----------------|----------------|--|
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Maternal exposure via partner during pregnancy | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Cardiac disorders | | | |
| Palpitations | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 7 (28.57%) | |
| occurrences (all) | 0 | 3 | |
| Nervous system disorders | | | |
| Ageusia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Headache | | | |
| subjects affected / exposed | 4 / 12 (33.33%) | 4 / 7 (57.14%) | |
| occurrences (all) | 6 | 12 | |
| Neuralgia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Restless legs syndrome | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 7 (14.29%) | |
| occurrences (all) | 1 | 1 | |
| Breakthrough haemolysis | | | |
| subjects affected / exposed | 4 / 12 (33.33%) | 4 / 7 (57.14%) | |
| occurrences (all) | 5 | 4 | |
| Haemolysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Lymphopenia | | | |

| | | | |
|-----------------------------|-----------------|----------------|--|
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 10 | 0 | |
| Neutropenia | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 7 (0.00%) | |
| occurrences (all) | 5 | 0 | |
| Splenomegaly | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 7 (0.00%) | |
| occurrences (all) | 4 | 0 | |
| Ear and labyrinth disorders | | | |
| Ear haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Tympanic membrane disorder | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 1 | |
| Vertigo | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Gastrointestinal disorders | | | |
| Abdominal distension | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 7 (14.29%) | |
| occurrences (all) | 1 | 4 | |
| Abdominal pain | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 2 / 7 (28.57%) | |
| occurrences (all) | 4 | 9 | |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 4 | |
| Ascites | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Colitis | | | |

| | | | |
|--|-----------------|----------------|--|
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Constipation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 7 (28.57%) | |
| occurrences (all) | 0 | 3 | |
| Diarrhoea | | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 4 | 2 | |
| Dyspepsia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 7 (14.29%) | |
| occurrences (all) | 1 | 1 | |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 7 (28.57%) | |
| occurrences (all) | 0 | 4 | |
| Gastritis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Nausea | | | |
| subjects affected / exposed | 4 / 12 (33.33%) | 1 / 7 (14.29%) | |
| occurrences (all) | 7 | 3 | |
| Toothache | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 1 / 7 (14.29%) | |
| occurrences (all) | 2 | 1 | |
| Vomiting | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 1 / 7 (14.29%) | |
| occurrences (all) | 3 | 1 | |
| Hepatobiliary disorders | | | |
| Jaundice | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 7 (14.29%) | |
| occurrences (all) | 1 | 1 | |
| Skin and subcutaneous tissue disorders | | | |
| Dermatitis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Dermatitis allergic | | | |

| | | | |
|---|----------------|----------------|--|
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 5 | 0 | |
| Erythema | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Pityriasis rosea | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Rash | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 8 | |
| Skin reaction | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Chromaturia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 7 (28.57%) | |
| occurrences (all) | 0 | 3 | |
| Dysuria | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Haemoglobinuria | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 4 / 7 (57.14%) | |
| occurrences (all) | 2 | 5 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) | |
| occurrences (all) | 0 | 1 | |
| Back pain | | | |

| | | | |
|--|----------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 3 / 12 (25.00%) 4 | 3 / 7 (42.86%) 4 | |
| Joint swelling subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 7 (14.29%) 1 | |
| Muscle spasms subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| Myalgia subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 2 / 7 (28.57%) 2 | |
| Infections and infestations | | | |
| Bacterial vaginosis subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 7 (14.29%) 1 | |
| Bronchitis subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| COVID-19 subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 7 (14.29%) 1 | |
| Folliculitis subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| Fungal infection subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 7 (14.29%) 1 | |
| Gastroenteritis viral subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 2 / 7 (28.57%) 2 | |
| Genital herpes subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 7 (14.29%) 2 | |
| Helicobacter gastritis subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |

| | | |
|-----------------------------------|-----------------|----------------|
| Hordeolum | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 |
| Infection | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 |
| Influenza | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 2 / 7 (28.57%) |
| occurrences (all) | 1 | 3 |
| Nasopharyngitis | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 3 / 7 (42.86%) |
| occurrences (all) | 2 | 6 |
| Pharyngitis | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 |
| Post procedural infection | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 |
| Rhinovirus infection | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 0 | 2 |
| Soft tissue infection | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 |
| Tonsillitis | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 |
| Tooth abscess | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 |
| Upper respiratory tract infection | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 4 | 1 |
| Urinary tract infection | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 3 | 1 |

| | | | |
|--|---------------------|---------------------|--|
| Viral infection subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 7 (14.29%) 1 | |
| Vulvovaginal candidiasis subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 1 / 7 (14.29%) 1 | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 1 / 7 (14.29%) 2 | |
| Dehydration subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| Folate deficiency subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 7 (14.29%) 3 | |
| Hypomagnesaemia subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| Hyponatraemia subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 7 (0.00%) 0 | |
| Vitamin B12 deficiency subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 7 (14.29%) 1 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|---|
| 18 August 2020 | Added an exclusion criterion for participants with elevated serum bilirubin. - Revised text for exclusion criteria for liver enzymes aspartate aminotransferase (AST) and alanine transaminase (ALT) for consistency with the new serum bilirubin exclusion criterion. - Added the requirement for participant discontinuation in the event of meningococcal infection or any serious infection that occurred after treatment was initiated. - Clarified that if the trial was to be halted due to safety concerns or based on a data monitoring committee (DMC) decision, restarting the trial would only occur following the appropriate authorization via a substantial amendment. |
| 12 November 2020 | Updated the visit schedule to every 4 week visits throughout the study for regular safety laboratory tests. Following findings of possible clinical chemistry changes in nonclinical toxicology studies, 4 week visits were continued after Week 24 as a precaution, - Updated text to include new nonclinical data. - Updated text to include new clinical data. - Clarification for tapering off or discontinuation of eculizumab or ravulizumab in former BCX9930 101 study participants who had added BCX9930 to their existing therapy with eculizumab or ravulizumab. - Updated information on prohibited medications. - Introduced additional text in case a new tablet formulation in development replaced the original hard gelatin capsule formulation. The introduction of the new tablet formulation was pending the results from a relative bioavailability study of the tablet and capsule formulations. |
| 24 June 2021 | Transitioned all participants from hard gelatin capsules to tablets. - Following assessment of the BCX9930-101 and BCX9930-201 study data, combined with pharmacokinetic (PK) modelling activities, it was concluded that 500 mg BID administered using the new tablet formulation was the most appropriate dose. This was the dose that was taken into the registration studies, BCX9930-202 and BCX9930-203. Therefore, all participants in this study were to take 500 mg BID with no dose modifications permitted. - Increased study treatment period from 48 weeks to 96 weeks to allow continued access following the assessment of chronic toxicology studies. - Updated the risk-benefit in accordance with the current available clinical and nonclinical data. - Updated the participant withdrawal criteria to provide adequate participant protection against treatment related injury following a review of the nonclinical data, and current available clinical data. - Updated dosing compliance language following availability of PK modelling data and transition to tablets. - Added laboratory parameters to strengthen ability to detect treatment emergent adverse changes. |
| 01 July 2022 | Participants enrolled into this study were to reach Week 96 in October and November 2022. Therefore, this amendment was submitted to extend the duration of treatment for an additional 48 weeks; i.e., up to Week 144. Additional measures for safety monitoring were included to mirror safety monitoring assessments in registration studies, BCX9930-202 and BCX9930-203. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The sponsor decided to prematurely terminate the study due to changes in the competitive landscape. Per change in planned analysis, data were analyzed and reported for safety and selected efficacy parameters

Notes: